Barclays PLC Theseus Pharmaceuticals, Inc. Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	BUY	$2.12 - $4.18 $51,441 - $101,427	24,265 Added 309.82%	32,097 $130,000
Q3 2023 Nov 07, 2023	SELL	$2.66 - $10.04 $1,417 - $5,351	-533 Reduced 6.37%	7,832 $21,000
Q2 2023 Aug 03, 2023	SELL	$7.28 - $11.82 $33,691 - $54,702	-4,628 Reduced 35.62%	8,365 $77,000
Q1 2023 May 04, 2023	BUY	$5.21 - $14.05 $21,303 - $57,450	4,089 Added 45.92%	12,993 $115,000
Q4 2022 Feb 13, 2023	BUY	$4.69 - $8.36 $18,028 - $32,135	3,844 Added 75.97%	8,904 $44,000
Q3 2022 Nov 03, 2022	SELL	$5.7 - $8.68 $752 - $1,145	-132 Reduced 2.54%	5,060 $29,000
Q2 2022 Aug 12, 2022	SELL	$5.04 - $14.05 $5,130 - $14,302	-1,018 Reduced 16.39%	5,192 $29,000
Q1 2022 May 16, 2022	BUY	$8.75 - $14.51 $54,337 - $90,107	6,210 New	6,210 $72,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.